NFKB1 and neoplasm: IKK1/2 inhibitor and knockdown of IKK1/2 also sensitize CRC cells to JQ1 treatment and repress c-myc and FOXM1 expression, indicating that NF-κB is the primary target for Bortezomib to synergize with JQ1 to inhibit tumor growth.